Universitatsklinikum Essen, West Germany Cancer Center

Site:	Universitatsklinikum Essen, West Germany Cancer Center
Address:	Hufelandstr. 55
City:	Essen
State:
Zip:	45122
Country:	Germany

17 trials at this site

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST	Active, not recruiting	Closed	Imatinib	NCT02413736
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
	Cross-Platform Biomarker Program for Establishment and Validation of Liquid Biopsy for Clinical Decision Making in resectable gastrointestinal stromal tumour (GIST)	Not yet recruiting	Not yet activated	ddPCR
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00568750
1	LBH589 Plus Imatinib	Ongoing, but not recruiting	Closed	Imatinib + Panobinostat
1	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Not yet activated	BEZ235 + MEK162	NCT01337765
1	Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + MEK162	NCT01363232
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
2	POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (POETIG)	Unknown	Active	Ponatinib (Iclusig)	NCT03171389
2	Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Not yet activated	Ripretinib plus Binimetinib	NCT05080621
			Active